Search - tctmd.com

Displaying 281 - 300 of 485

Sort: Relevancy | Date

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Industry News

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

July 25, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Daily News

Predictors of Bad Outcomes After Unprotected Left Main Disease Similar Regardless of Treatment

Todd Neale

July 20, 2017

News Daily News

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Michael O'Riordan

July 10, 2017

News Daily News

Traditional Chinese Medicine May Aid in Prevention of Cardiovascular Disease

L.A. McKeown

June 12, 2017

News Daily News

Viper Peptides Explored Anew as Antiplatelet Drugs

Yael L. Maxwell

June 08, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Shelley Wood

April 24, 2017

News Daily News

Who Should Get a Statin? Guidelines Don’t Match Up

Michael O'Riordan

April 20, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Updated AUC for Stable Ischemic Heart Disease Seek to Match ‘Appropriateness’ to Current Practice

Caitlin E. Cox

March 10, 2017

News Daily News

Meta-analysis Calls Into Question Strength of Guidance for RAS Blockade in Patients With Stable CAD

Todd Neale

January 19, 2017

Advertisement

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Predictors of Bad Outcomes After Unprotected Left Main Disease Similar Regardless of Treatment

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Traditional Chinese Medicine May Aid in Prevention of Cardiovascular Disease

Viper Peptides Explored Anew as Antiplatelet Drugs

TCTMD’s Top 10 Most Popular Stories for May 2017

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Who Should Get a Statin? Guidelines Don’t Match Up

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Updated AUC for Stable Ischemic Heart Disease Seek to Match ‘Appropriateness’ to Current Practice

Meta-analysis Calls Into Question Strength of Guidance for RAS Blockade in Patients With Stable CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content